Loading…
← CockpitCompetitor Analysis › 42C.SI iX Biopharma Ltd.Open in the cockpit ↗

iX Biopharma Ltd.42C.SICompetitor analysis, valuation and peers

Singapore · SGD·Health Care›Pharmaceuticals: Major
Momentum leader 91
Mkt cap
$387M
US dollars, full cap
Free float
61%
of shares outstanding
$/day
$2.51M
20-day average traded
Fwd P/E
n/m
no positive forecast
ROIC−WACC
-132.8 pp
WACC 10.6%
Hurdle
n/a
no reverse DCF
Next earnings
79 days
5 Feb 2027
Close · SGDS$0.46
1D0.0%
1W-9.9%
1M-13.3%
3M-4.2%
6M+28.2%
YTD+234.6%
1Y+255.5%
ATR %6.2%
52w lowhigh27.2% off high

What iX Biopharma does

Employees: 48

iX Biopharma at a glance

Size iX Biopharma (42C.SI) is a Singapore Health Care company (Pharmaceuticals: Major) with a market value of $387M, the 121st largest of 184 Singapore companies the cockpit tracks. Shares closed at S$0.46 on 18 Nov 2026.

Performance Over six months the shares gained 28.2%, against -23.1% for the median peer and -4.6% for the Singapore market (cap-weighted) — 2nd highest of 19 in its peer set.

Growth Revenue fell 11.8% over the last twelve months (peer median -2.8%); the operating margin is -139.5% (peer median -7.8%).

Valuation It trades at 71.6× enterprise value to sales against a peer median of 4.9× (3rd most expensive of 18).

Capital Return on invested capital runs 132.8 points below its cost of capital (10.6% WACC).

Next results Next results expected around 5 Feb 2027 (exchange calendar; dates can move).

Relative performance

10015021 May 202621 Aug 202618 Nov 202642C.SI 135Peer median 79
Six months, rebased to 100: iX Biopharma against the median of its 20 peers (local-currency closes).

iX Biopharma financials

Reported figures in SGD; fiscal year ends 2026-06-30. TTM = trailing twelve months.
TTMFY2026FY2025FY2024FY2023
Revenuen/aS$6.85MS$7.77MS$5.96MS$5.91M
Revenue growth—-12%+30%+1%—
Gross profitn/aS$2.43MS$2.04MS$1.05MS$2.32M
EBITDAn/a-S$8.83M-S$5.43M-S$6.63M-S$9.71M
Net incomen/a-S$7.99M-S$10.1M-S$10.8M-S$9.62M
Free cash flown/a-S$8.07M-S$4.59M-S$7.09M-S$8.63M
Capital expendituren/aS$117,000S$201,000S$285,000S$695,000
Total debtS$3.44MS$5.80MS$5.90MS$5.20MS$4.34M

Quarterly statements and history in the cockpit →

iX Biopharma competitor charts

The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.

Performance: 6-month against 1-month return

-50%0%+50%-40%-20%0%300534AVTX4592300452002868219A4552IRD300636688399PBYI002872002581MPLT653530111142C.SI6-month return →1-month return →
Up and to the right = strong over both horizons. iX Biopharma is the large dot.

Fundamentals: revenue growth against valuation

0%+100%+200%0×200×400×SHUKRAPHAR300534300452002868219AIRDPBYI002581653542C.SIRevenue growth (TTM) →EV / Sales →
Further right = faster growth; higher = more expensive. The dashed lines are the peer medians. iX Biopharma is the large dot.

iX Biopharma competitors and peer comparison

How iX Biopharma compares with its peers

Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.

iX Biopharma against its 20 peers (data as of 18 Nov 2026)
Measure42C.SIPeer medianRank in peer set
1-month return-13.3%-12.7%9th lowest of 20
6-month return+28.2%-23.1%2nd highest of 19
Distance from 52-week high-27.2%-44.6%5th highest of 21
Revenue growth (TTM)-11.8%-2.8%8th lowest of 18
Operating margin-139.5%-7.8%6th lowest of 19
EV / Sales71.6×4.9×3rd most expensive of 18
ROIC minus cost of capital-132.8 pp-5.4 pp3rd lowest of 17

Peer table

Peer set: Industry: the same industry and sector in any market, nearest in size
CompanyMarketMarket cap6M returnRevenue growthOp. marginEV / SalesReq gDelivered g
iX Biopharma 42C.SISingapore$387M+28%-12%-140%71.6×n/an/a
Shukra Pharmaceuticals SHUKRAPHAR.NSIndia$387Mn/a+222%54%32.0×n/an/a
Gansu Longshenrongfa Pharmaceutical Industry 300534.SZChina$386M-2%-21%8%3.7×20.9%+28.2%
Avalo Therapeutics AVTXUnited States$387M-59%-69%-161,961%n/an/an/a
SanBio 4592.TJapan$386M-55%n/an/an/an/an/a
Anhui Sunhere Pharmaceutical Excipients 300452.SZChina$388M-17%+9%19%2.2×-5.5%+12.2%
Lifecome Biochemistry 002868.SZChina$384M-54%-23%-3%6.2×n/an/a
Heartseed 219A.TJapan$392M+53%+197%9%21.9×46.5%+73.2%
JCR Pharmaceuticals 4552.TJapan$379M-5%+3%-14%2.9×n/an/a
Opus Genetics IRDUnited States$379M-22%-46%-778%41.2×n/an/a
Jiangxi Synergy Pharmaceutical 300636.SZChina$398M-13%-3%2%3.4×14.9%+13.7%
Jiangsu Bioperfectus Technologies 688399.SSChina$374M-51%-8%-23%4.4×n/an/a
Puma Biotechnology PBYIUnited States$373M+3%+9%11%1.2×0.1%+0.3%
ARS Pharmaceuticals SPRYUnited States$371M-53%-14%-162%2.9×n/an/a
Tiansheng Pharmaceutical 002872.SZChina$371M-1%-1%-13%4.9×22.2%-15.7%
Shandong Sinobioway Biomedicine 002581.SZChina$405M-24%+91%-65%7.9×n/an/a
MapLight Therapeutics MPLTUnited States$370M-76%n/an/an/an/an/a
Beijing Centergate Technologies (Holding) 000931.SZChina$406M-18%-16%2%1.9×9.2%+6.7%
Lumosa Therapeutics 6535.TWOTaiwan$406M-37%-25%-803%399.1×n/an/a
6467 6467.TWTaiwan$368Mn/an/a-2,618%1,407.9×n/an/a
Guangdong Lifestrong Pharmacy 301111.SZChina$368M-33%+7%-2%7.2×n/an/a

Questions

Which companies are iX Biopharma's closest peers?
The cockpit's peer set: Shukra Pharmaceuticals (SHUKRAPHAR.NS), Gansu Longshenrongfa Pharmaceutical Industry (300534.SZ), Avalo Therapeutics (AVTX), SanBio (4592.T), Anhui Sunhere Pharmaceutical Excipients (300452.SZ), Lifecome Biochemistry (002868.SZ), Heartseed (219A.T), JCR Pharmaceuticals (4552.T).
Is iX Biopharma expensive compared with its peers?
On ev / sales it trades at 71.6× against a peer median of 4.9×, 3rd most expensive of 18 in its peer set.
How has iX Biopharma stock performed?
Over six months to 18 Nov 2026 the shares returned +28.2% against -23.1% for the median peer; over one year +255.5%.

How these numbers are made. Returns are close-to-close in local currency. Revenue growth and margins are trailing twelve months. Req g is the revenue growth that today's enterprise value requires for seven years at the company's own cost of capital; Delivered g is what it actually grew; the gap is the hurdle (honest precision about ±8 points, so read the ranking more than the decimal). No fair values, price targets or analyst ratings are shown, by design. Method and validation.